<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971789</url>
  </required_header>
  <id_info>
    <org_study_id>080151</org_study_id>
    <secondary_id>08-C-0151</secondary_id>
    <nct_id>NCT00971789</nct_id>
    <nct_alias>NCT00722449</nct_alias>
  </id_info>
  <brief_title>Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes</brief_title>
  <official_title>A Pilot Study of Sirolimus (Rapamycin, Rapamune[Registered Trademark]) in Subjects With Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      People with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) hamartomatous
      tumor syndromes (PHTS) have a mutation in one of their genes called PTEN that can lead to
      benign tumors called hamartomas throughout the body. This puts them at increased risk for
      breast, thyroid and endometrial cancer.

      People with a PTEN mutation have increased activity of proteins such as protein kinase B
      (AKT) and mammalian target of rapamycin (mTOR), which may be responsible for tumor growth and
      their increased risk of these cancers.

      Experiments show that a drug called sirolimus, which is used to prevent the immune system
      from rejecting transplanted organs, can inhibit cancer cell growth by blocking the mTOR
      protein.

      Objectives:

      To test the ability of sirolimus to decrease the activity of proteins that are regulated by
      mTOR in both benign and cancerous tumor tissue.

      Eligibility:

      People 18 years of age and older with Cowden syndrome or other PHTS.

      Design:

      Sirolimus treatment. Patients take sirolimus once a day in 28-day treatment cycles. Patients
      who do not have cancer take the drug for a total of two cycles (56 days) unless they develop
      unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until
      their disease worsens or they develop unacceptable side effects.

      Evaluations. Patients come to the clinic for a history and physical examination on day 1 of
      every treatment cycle, then every month for the first two months off therapy, and then at 6
      and 12 months. In addition, they have the following procedures:

        -  Positron emission tomography (PET) scan and neuropsychological testing before starting
           treatment.

        -  Clinical photography (photographic documentation of skin lesions) before starting
           treatment. Patients who do not have cancer have repeat photography at 2 and 8 weeks and
           then, if the lesions shrink or go away while on therapy, again every month for the first
           2 months off sirolimus, then at 6 months and 1 year. Patients who have cancer and
           continue treatment beyond 8 weeks have repeat photography every 8 weeks while on the
           study.

        -  Digital dermoscopy (skin lesion examination using a high resolution camera). This is
           done at the same intervals as clinical photography.

        -  Multiple biopsies of the skin and lower intestine, and possibly the tumor in patients
           with cancer, before starting treatment, at 2 weeks of treatment and at 8 weeks of
           treatment.

        -  Blood and urine tests every week while on treatment for the first two cycles, then every
           4 weeks for patients who continue treatment beyond two cycles.

        -  Imaging studies, such as computerized tomography (CT), ultrasound or magnetic resonance
           imaging (MRI) in patients with cancer before starting treatment and again every two
           cycles to monitor the tumor size and location.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor suppressor
           gene whose function is frequently lost through genetic and epigenetic mechanisms in
           cancer. Loss of PTEN increases activation of the phosphoinositide 3-kinase
           (PI3K)/Akt/mTOR pathway, which increases cellular proliferation and survival.

        -  Germline mutations in PTEN are associated with a number of hamartomatous syndromes, of
           which Cowden Syndrome (CS) is the prototype. The set of syndromes that are defined by
           germline PTEN mutations has been labeled PTEN Hamartomatous Tumor Syndromes or PHTS.

        -  Patients with PHTS suffer increased morbidity and mortality. Benign tumors such as
           hamartomas occur in virtually every organ, most commonly in the skin and the
           gastrointestinal tract, which prompts frequent monitoring and resection and causes
           psychological and physical stressors on patients with this condition.

        -  Cowden syndrome (CS) patients develop thyroid, breast, and endometrial cancers at an
           earlier age than the general population, and have an overall increased incidence of
           these cancers compared to the general population. These patients have increased
           morbidity from heightened surveillance and diagnostic procedures.

        -  No medical therapies exist for PHTS patients.

        -  Because tumors from PHTS patients show increased activation of the PI3K/Akt/mTOR
           pathway, inhibitors of this pathway might have activity in patients with PHTS.

        -  Sirolimus (rapamycin) is a specific inhibitor of mTOR that is Food and Drug
           Administration (FDA)-approved and is preferentially effective in cells with mutant PTEN.

        -  We hypothesize that sirolimus will have activity in patients with PHTS, as measured by
           biochemical techniques that will assess mTOR inhibition and clinical tests that will
           assess the growth and metabolism of benign and malignant tumors.

      Objectives:

        -  The primary endpoint will be inhibition of the mTOR pathway in tissues obtained before
           and after therapy, as assessed using immunohistochemistry in benign as well as malignant
           tumors.

        -  Secondary endpoints will include inhibition of the mTOR pathway in peripheral blood
           mononuclear cells (PBMCs) as assessed by immunoblotting, changes and duration of change
           in benign or malignant tumor size as assessed by computed tomography (CT), serial
           digital photography, digital dermoscopy, changes in tumor metabolism as assessed by
           positron emission tomography (PET), changes in lymphocyte counts, as well as changes in
           neuropsychological testing.

      Eligibility:

      -Adult subjects with documented germline PTEN mutations who meet diagnostic criteria for
      Cowden Syndrome by international criteria.

      Design:

        -  Subjects will undergo biopsy, imaging, photography, dermoscopy, and neuropsychological
           testing prior to and after a course of therapy with sirolimus to assess the efficacy of
           treatment.

        -  This pilot protocol will test sirolimus at an FDA-approved dose (6 mg by mouth (PO)
           loading dose/ 2mg PO daily) in a group of twenty patients.

        -  Treatment will last for 56 days (plus 2 - 3 days to allow flexibility for scheduling of
           follow-up procedures) for PHTS subjects with benign hamartomatous tumors.

        -  For PHTS subjects with established malignancy, measurement of disease will be performed
           every other cycle and treatment will continue until disease progression or unacceptable
           toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.</measure>
    <time_frame>Baseline, day 14, and day 56</time_frame>
    <description>A biochemical change is defined as a decrease in certain protein levels (e.g. P-AKT (phosphorylated AKT), total S6, P-S6, and P-4E-BP1) important in cell growth. These are measured by collecting tissue samples which stained and protein levels are measured under the microscope. Scoring will be based on distribution and intensity of staining. Distribution will be scored as 0 (0%), 1 (1% to 50%), and 2 (51% to 100%) to indicate the percentage of positive cells of interest in a single core. The intensity of the signal will be scored as 1 (weak), 2 (moderate), and 3 (strong). The distribution score and intensity score will be summed into a total score (TS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>47 months</time_frame>
    <description>Here is the number of participants with adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cowden's Disease</condition>
  <condition>Hamartoma Syndrome, Multiple</condition>
  <arm_group>
    <arm_group_label>Sirolimus Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.</description>
    <arm_group_label>Sirolimus Patients</arm_group_label>
    <other_name>FDG-18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects</description>
    <arm_group_label>Sirolimus Patients</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Videography</intervention_name>
    <description>This examination involves testing of cerebellar function that controls movement, balance, and coordination.</description>
    <arm_group_label>Sirolimus Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA:

          1. Patients must have documented germline phosphatase and tensin homolog deleted on
             chromosome 10 (PTEN) mutation performed in a Clinical Laboratory Improvement
             Amendments (CLIA) approved laboratory.

          2. Patients must meet clinical criteria for Cowden Syndrome.

          3. Patients must have the capacity to provide informed consent and demonstrate
             willingness to comply with an oral regimen.

          4. Patients must have at least 6 sites amenable to biopsy within the skin and/or
             gastrointestinal (GI) tract and /or accessible malignant tumor (for patients with
             malignancy) and agree to the biopsy of these sites prior to and following sirolimus
             administration.

          5. Patients do not need to have malignant tumors, but if they do, they must have relapsed
             or failed to respond to standard therapy, and the patient's current disease state must
             be one for which there is no known curative therapy. Patients who are diagnosed with
             cancer as a consequence of initial positron emission tomography (PET)/computerized
             tomography (CT) scan will be managed according to the flow diagram illustration.

          6. Patients must have not received chemotherapy in the 28 days prior to enrollment.

          7. Age greater than or equal to 18 years of age.

          8. Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to
             2.

          9. An expected survival of greater than or equal to 3 months.

         10. Patients must consent to the use of effective barrier-based contraception during the
             course of treatment and for three months following discontinuation of treatment.

         11. Patients must have normal organ and marrow function as defined below:

               -  absolute neutrophil count greater than or equal to 1,500/mL.

               -  platelets greater than or equal to 100,000/mL.

               -  total bilirubin less than 1.5 times upper limit of institutional normal.

               -  Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase(SGOT)
                  less than or equal to 2.5 times upper limit of institutional normal.

               -  Alanine aminotransferase (ALT) serum glutamic pyruvic transaminase(SGPT) less
                  than or equal to 2.5 times upper limit of institutional normal.

               -  Creatinine less than 1.5 times upper limit of institutional normal.

         12. PHTS subjects with benign hamartomatous disease must have controlled fasting low
             density lipoprotein (LDL) and triglyceride levels as defined by National Cholesterol
             Education Program Adult Treatment Panel III (NCEP ATP III) guidelines. Please see
             section 3.5 for further details.

         13. Patients must have recovered from any acute toxicity related to prior treatments,
             including surgery. Toxicity should be &lt; grade 1 or returned to baseline.

         14. If a patient withdraws consent within two weeks of starting study drug, he/she may
             request to re-enter study at the principal investigators (PI's) discretion by
             re-signing consent and being re-registered through the Central Registration Office
             (CRO) using the initial baseline studies. Sirolimus taken during the period on study
             (prior to withdrawal of consent) will not be considered as prior sirolimus therapy
             that otherwise would exclude enrollment.

        EXCLUSION CRITERIA:

          1. Pregnant or lactating women, due to potentially harmful effects of sirolimus on the
             embryo or fetus or nursing child.

          2. Any concurrent therapy with chemotherapeutic agents or biologic agents or radiation
             therapy.

          3. Patients taking immuno-suppressive agents other than prescribed corticosteroids, which
             must not exceed the equivalent of 20 mg/d of prednisone.

          4. Patients that are on the following cytochrome P450 3A4 (CYP3A4) inhibitors and cannot
             replace these medications with other equivalent medications for the period of the
             study: protease inhibitors, cyclosporine, fluconazole, itraconazole, ketoconazole,
             metoclopramide, felodipine, nifedipine, carbamazepine, Phenobarbital, grapefruit
             juice, and St. John's Wort.

          5. Patients who have received live vaccines in the past 30 days.

          6. Patients with human immunodeficiency virus (HIV) seropositivity, due to potential drug
             interactions between sirolimus and anti-retroviral medications, as well as the unknown
             effects of single agent sirolimus on the immune system in HIV patients.

          7. Patients with interstitial lung disease or pneumonitis.

          8. Patients with bleeding diathesis.

          9. Patients with prior or active pneumocystis jirovecii (PJP) pneumonia.

         10. Patients with prior use of rapamycin, a rapamycin analogue, or other mTOR inhibitor.

         11. Patients who do not agree to have multiple repeated biopsies performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun Rajan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-C-0151.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943-7.</citation>
    <PMID>9072974</PMID>
  </reference>
  <reference>
    <citation>Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltom√§ki P, de la Chapelle A, Aaltonen LA, Eng C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002 Aug;161(2):439-47.</citation>
    <PMID>12163369</PMID>
  </reference>
  <reference>
    <citation>Zhou X, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, Parisi M, Winter RM, Eng C. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet. 2001 Jul 21;358(9277):210-1.</citation>
    <PMID>11476841</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <results_first_submitted>May 3, 2013</results_first_submitted>
  <results_first_submitted_qc>July 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2013</results_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Arun Rajan, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Sirolimus</keyword>
  <keyword>Cowden Syndrome</keyword>
  <keyword>PTEN Mutation</keyword>
  <keyword>Hamartoma Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hamartoma</mesh_term>
    <mesh_term>Hamartoma Syndrome, Multiple</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus Patients</title>
          <description>sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus Patients</title>
          <description>sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.54" spread="15.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.</title>
        <description>A biochemical change is defined as a decrease in certain protein levels (e.g. P-AKT (phosphorylated AKT), total S6, P-S6, and P-4E-BP1) important in cell growth. These are measured by collecting tissue samples which stained and protein levels are measured under the microscope. Scoring will be based on distribution and intensity of staining. Distribution will be scored as 0 (0%), 1 (1% to 50%), and 2 (51% to 100%) to indicate the percentage of positive cells of interest in a single core. The intensity of the signal will be scored as 1 (weak), 2 (moderate), and 3 (strong). The distribution score and intensity score will be summed into a total score (TS).</description>
        <time_frame>Baseline, day 14, and day 56</time_frame>
        <population>No patient underwent biopsy after the study treatment, so no such tissue analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Patients</title>
            <description>sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.</title>
          <description>A biochemical change is defined as a decrease in certain protein levels (e.g. P-AKT (phosphorylated AKT), total S6, P-S6, and P-4E-BP1) important in cell growth. These are measured by collecting tissue samples which stained and protein levels are measured under the microscope. Scoring will be based on distribution and intensity of staining. Distribution will be scored as 0 (0%), 1 (1% to 50%), and 2 (51% to 100%) to indicate the percentage of positive cells of interest in a single core. The intensity of the signal will be scored as 1 (weak), 2 (moderate), and 3 (strong). The distribution score and intensity score will be summed into a total score (TS).</description>
          <population>No patient underwent biopsy after the study treatment, so no such tissue analysis was done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events</description>
        <time_frame>47 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Patients</title>
            <description>sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus Patients</title>
          <description>sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other (anemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>CD4 count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dental: teeth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (bloating)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI::Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)::Oral cavity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain::Abdomen NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain - Other (R/costal vert. angle; R/flank; shoulder)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Eye NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesteremia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Extremity-limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain::Joint</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain::Muscle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain::Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mood alteration::Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain::Head/headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine color change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menses (change from baseline)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain::Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular - Other (venous insufficiency)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arun Rajan</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-594-5322</phone>
      <email>rajana@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

